Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis

Angiogenesis

Volumn 19, Issue 1, 2016, Pages 39-52

  Semerano, Luca ^a,b   Duvallet, Emilie ^a   Belmellat, Nadia ^a   Marival, Nicolas ^a,c   Schall, Nicolas ^d   Monteil, Maëlle ^a,e   Grouard Vogel, Géraldine ^f   Bernier, Emilie ^f   Lecouvey, Marc ^a,e   Hlawaty, Hanna ^a,c   Muller, Sylviane ^d   Boissier, Marie Christophe ^a,b   Assier, Eric ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^e UMR 7244   (France)

^f Neovacs SA   (France)

Author keywords

Arthritis; Inflammation; Peptides; Vaccines; VEGF

Indexed keywords

COLLAGEN ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; TYPE II COLLAGEN ANTIBODY; UNCLASSIFIED DRUG; VACCINE; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VEGF K PEPTIDE; VPEP1 K PEPTIDE; VPEP2 K PEPTIDE; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EXPERIMENTAL ARTHRITIS; HUMORAL IMMUNITY; IC50; IMMUNIZATION; JOINT DESTRUCTION; MALE; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SYNOVIAL VASCULARIZATION; SYNOVITIS; VASCULARIZATION; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; CHEMISTRY; HUMAN; IMMUNOLOGY; INFLAMMATION; JOINT; MOLECULAR GENETICS; PATHOLOGY; SYNOVIUM; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; INFLAMMATION; JOINTS; MALE; MICE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDES; SYNOVIAL MEMBRANE; VACCINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84952982472     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-015-9487-0     Document Type: Article

References (52)

1. Hirohata S, Sakakibara J (1999) Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 353:1331
2. Mansson B, Carey D, Alini M et al (1995) Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 95:1071–1077
3. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125–1132
4. Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232–234
5. Miossec P (2003) Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 48:594–601
6. Semerano L, Clavel G, Assier E, Denys A, Boissier MC (2011) Blood vessels, a potential therapeutic target in rheumatoid arthritis? Joint Bone Spine 78:118–123
7. Kremer JM, Blanco R, Brzosko M et al (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63:609–621
8. Otrock ZK, Makarem JA, Shamseddine AI (2007) Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38:258–268
9. Shibuya M (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9:225
10. Clavel G, Valvason C, Yamaoka K et al (2006) Relationship between angiogenesis and inflammation in experimental arthritis. Eur Cytokine Netw 17:202
11. Clavel G, Marchiol-Fournigault C, Renault G et al (2008) Ultrasound and Doppler micro-imaging in a model of rheumatoid arthritis in mice. Ann Rheum Dis 67:1765–1772
12. Lu J, Kasama T, Kobayashi K et al (2000) Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164:5922–5927
13. De Bandt M, Ben Mahdi MH, Ollivier V et al (2003) Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol 171:4853–4859
14. Le Buanec H, Delavallée L, Bessis N et al (2006) TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci USA 103:19442–19447
15. Delavallée L, Le Buanec H, Bessis N et al (2008) Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 67:1332–1338
16. Semerano L, Biton J, Delavallée L et al (2013) Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levels. Clin Exp Immunol 172:54–62
17. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer SM (2013) The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors–a meta-analysis and systematic review. PLoS One 8:e51780
18. Rad FH, Le Buanec H, Paturance S et al (2007) VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104:2837–2842
19. Muller YA, Christinger HW, Keyt BA, de Vos AM (1997) The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure 5:1325–1328
20. Kong JS, Yoo SA, Kim JW et al (2010) Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis Rheum 62:179
21. Starzec A, Vassy R, Martin A et al (2006) Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 79:2370–2371
22. Iyer S, Leonidas DD, Swaminathan GJ et al (2001) The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 276:12153–12161
23. Parker MW, Xu P, Li X, Vander Kooi CW (2012) Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 287:11082–11089
24. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M (1997) Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 272:31582–31588
25. Miellot A, Zhu R, Diem S et al (2005) Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 35:3704–3713
26. Murakami M, Iwai S, Hiratsuka S et al (2006) Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. Blood 108:1849–1856
27. Nam EH, Park SR, Kim PH (2010) TGF-beta1 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions. Exp Mol Med 42:606–613
28. Kim WU, Kang SS, Yoo SA et al (2006) Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. J Immunol 177:5727–5735
29. Terme M, Tartour E, Taieb J (2013) VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. Oncoimmunology 2:e25156
30. Hansen W, Hutzler M, Abel S et al (2013) Neuropilin 1 deficiency on CD4 + Foxp3 + regulatory T cells impairs mouse melanoma growth. J Exp Med 209:2001–2006
31. Terme M, Pernot S, Marcheteau E et al (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539–539
32. Boissier MC, Assier E, Biton J et al (2009) Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 76:10–14
33. Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33–39
34. Biton J, Semerano L, Delavallée L et al (2011) Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 186:3899
35. Biton J, Boissier MC, Bessis N (2012) TNFα: activator or inhibitor of regulatory T cells? Joint Bone Spine 79:119–123
36. Nie H, Zheng Y, Li R et al (2013) Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med 19:322–328
37. Thiolat A, Semerano L, Pers YM et al (2014) Interleukin-6 receptor blockade enhances CD39 + regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 66:273–283
38. Cortes J, Calvo V, Ramirez-Merino N et al (2012) Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol 23:1130–1137
39. Zagury D, Burny A, Gallo RC (2001) Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci USA 98:8024–8029
40. Bertin-Maghit SM, Capini CJ, Bessis N et al (2005) Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 23:4228–4235
41. Capini CJ, Bertin-Maghit SM, Bessis N et al (2004) Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 22:3144–3153
42. Ratsimandresy RA, Duvallet E, Assier E et al (2011) Active immunization against IL-23p19 improves experimental arthritis. Vaccine 29:9329–9336
43. Hah YS, Koh YJ, Lim HS et al (2013) Double-antiangiogenic protein DAAP targeting vascular endothelial growth factor A and angiopoietins attenuates collagen-induced arthritis. Arthritis Res Ther 15:R85
44. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784
45. Saidenberg-Kermanac’h N, Corrado A, Lemeiter D et al (2004) TNF-a antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200–1207
46. Wang Y, Da G, Li H et al (2013) Avastin exhibits therapeutic effects on collagen-induced arthritis in rat model. Inflammation 36:1460–1467
47. Nagai T, Sato M, Kutsuna T et al (2010) Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair. Arthritis Res Ther 12:R178
48. Yu L, Wu X, Cheng Z et al (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49:522–527
49. Choi ST, Kim JH, Seok JY et al (2009) Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 28:333–337
50. Yoo SA, Bae DG, Ryoo JW et al (2005) Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 174:5846–5855
51. Delavallée L, Semerano L, Assier E et al (2009) Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 11:R195
52. Durez P, Vandepapeliere P, Miranda P et al (2014) Therapeutic vaccination with TNF-kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS One 9:e113465